Metabolic dysfunction-associated steatohepatitis+1
Not recruitingStudy on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3
Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3
- Disease:Metabolic dysfunction-associated steatohepatitisNon-alcoholic steatohepatitis
- Substances:Lanifibranor
France- Participants:18–64 years · 65+ years
- Substances:Lanifibranor
